Harrow, Inc. Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
Harrow, Inc. (HROW) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of $1.60 thousand for the 3-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-03-18
- Harrow, Inc. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for the quarter ending 2012-12-31 was $1.60K.
- Harrow, Inc. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2011 was $0.00.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 3 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|---|
| 2012-12-31 | $1.60K 10-K · filed 2013-03-18 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |